about
Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.Genotoxicity in Mice Following AAV Gene Delivery: A Safety Concern for Human Gene Therapy?Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectorsRecombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and PatientsTALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesGene editing technology as an approach to the treatment of liver diseases.Adeno-Associated Virus Gene Therapy for Liver Disease.Cell and gene therapy strategies to eradicate HIV reservoirsPlasmodium meets AAV-the (un)likely marriage of parasitology and virology, and how to make the match.Current and future prospects for hemophilia gene therapy.Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.AAV Infection: Protection from Cancer.Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA.Reply to "Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV"Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV.Gene Therapy for Hemophilia: Progress to Date.AAVvector-mediated in vivo reprogramming into pluripotency
P2860
Q33881920-FD659C72-08B4-4712-BD95-6C67A2A8C8D8Q36756903-4396E3D0-DEB8-4061-B87E-0B1E3FA4A647Q36867801-F790023B-C148-4382-9499-BA8A1F1909C4Q37043497-171FA0CC-3410-4AB7-B55D-B92D09B64368Q37577414-9496E46E-87CA-4CC6-B09F-308BC49C5C4EQ37621530-FF46C069-F322-49A9-987F-4AEF9656EEE6Q38749884-BB097B08-09C0-4558-8026-E9C572980690Q38789554-125EE715-E5B5-45A6-9B71-ED9217B51247Q38794293-330EE5A1-6B27-436A-B2B3-6BCAA269A197Q38818422-EDDE0929-5579-4C9B-89D3-7A2C8199F939Q38827606-1ACD50CC-B2BD-4C11-8C2E-04EB61ED751BQ40154601-161ACB68-5C9A-41C6-8E0A-CE25FCE6C9BFQ40457152-52474E8B-443F-4041-8315-9C2E6B809842Q40595052-2A47013D-0655-400F-9E99-107BC7055FEFQ42749763-290D9C43-2B9B-4E5F-A2B7-C721CFD0F0CEQ42749767-08B57DA1-1FCA-41AA-BFDD-3FCAD3729B66Q45874307-98419624-4AD8-4D23-8CE9-308235EAF8D6Q57562597-05324242-0107-4851-BC6B-1CD53CD41D18
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Adeno-associated Vector Toxicity-To Be or Not to Be?
@en
Adeno-associated Vector Toxicity-To Be or Not to Be?
@nl
type
label
Adeno-associated Vector Toxicity-To Be or Not to Be?
@en
Adeno-associated Vector Toxicity-To Be or Not to Be?
@nl
prefLabel
Adeno-associated Vector Toxicity-To Be or Not to Be?
@en
Adeno-associated Vector Toxicity-To Be or Not to Be?
@nl
P2860
P356
P1433
P1476
Adeno-associated Vector Toxicity-To Be or Not to Be?
@en
P2093
Hildegard Büning
Manfred Schmidt
P2860
P304
P356
10.1038/MT.2015.182
P577
2015-11-01T00:00:00Z